Prospective trials of angiotensin receptor blockers: Beyond blood pressure control

Conclusions  Current knowledge implicating the involvement of angiotensin II in both the development of hypertension and the pathophysiology of congestive heart failure, myocardial infarction, atherosclerosis, and vascular disease will open the door for more clinical trials involving angiotensin receptor blockers. Current and future studies should clearly answer the question of whether these drugs will play a major role in reducing morbidity and mortality from these diseases. If possible, these studies should attempt to further explain the role of angiotensin II and its receptors in the development of cardiovascular diseases.